Navigation Links
Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share
Date:2/4/2009

SEATTLE, Feb. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today that it has issued 6,634 shares of Series F Preferred Stock in exchange for 6,634 shares of CTI's Series A, B and C Convertible Preferred Stock. The exchange constitutes 83% in interest of all series of CTI's Convertible Preferred Stock. Each share of the new Preferred Stock will become convertible into 7,143 shares of CTI's common stock, at a conversion price of $0.14 per common share representing a significant premium to the current market price.

The Series F Preferred Stock cannot become convertible into common stock sooner than April 1, 2009. Additionally, the Company has the ability to redeem all, but not less than all, of the outstanding Series F Preferred Stock for cash when the Volume-Weighted Average Price (VWAP) has exceeded $0.28 for ten previous trading days. The Series F Preferred Stock does not provide a redemption right for the holders as did the Series A, B and C Convertible Preferred Stock, thereby eliminating the possibility that the Company could be required to make involuntary cash redemption payments of approximately $6.6 million on the preferred stock that was exchanged. The Series F Preferred Stock does not bear a fixed dividend rate.

"We are pleased that almost all of the remaining preferred shareholders were willing to trade in their securities and enable CTI to avoid their redemption rights and dividend payments, saving the company approximately $6.6 million over the next 6 months, for a meaningful equity position in the Company upon their conversion into common stock," noted James A. Bianco, M.D., CEO of CTI. "With the prospects for three drug approvals in 2009, we believe they chose to participate based on the price appreciation potential of CTI should we be successful with the approvals this year."

About Cell Therapeutics, Inc.

Headquartered i
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
2. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
3. Omnitura Therapeutics Announces Private Placement Financing
4. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
5. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
6. CV Therapeutics Statement on Unsolicited Proposal From Astellas
7. Cell Therapeutics Receives Additional NASDAQ Notification
8. Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes
9. Frost & Sullivan Recognizes ESBATechs Innovation in Developing Antibody Fragments for Biologic Therapeutics
10. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
11. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... 07, 2015 , ... Currently deployed within several large scale ... solve many of the complex logistical and data management challenges associated with physical ... and/or remote data coordination centers. , CentrePoint drastically reduces personnel training requirements ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... offers new insights into how virulent fungi adapt through genetic modifications to fight ... that battle leaves them temporarily weakened. These insights may provide clues to new ...
(Date:7/6/2015)... , July 6, 2015  Emdeon ... into a definitive agreement to acquire Altegra ... intervention platforms that combine data aggregation and ... capabilities to achieve actionable insights and improved ... combine Altegra Health,s risk adjustment and quality ...
(Date:7/6/2015)... 6, 2015  Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company ... , Viveve,s Chief Executive Officer, and Scott Durbin , ... July 9, 2015. , , , DATE:    ... , , TIME:     , , , 12:15 PM ... , http://tinyurl.com/viveve   ,    ...
Breaking Biology Technology:ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 2ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Emdeon to Acquire Altegra Health 2Emdeon to Acquire Altegra Health 3Emdeon to Acquire Altegra Health 4Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3
... SANTA ANA, Calif., Jan. 12 ,Abbott ( NYSE: ABT ) ... announced,today a definitive agreement for Abbott to acquire AMO for ... approximately $2.8 billion, inclusive,of estimated net debt at the time ... global leader in ophthalmic care, comprised of three segments: cataract,surgery, ...
... 12 Bavarian Nordic,owns several United States patents ... technology, MVA-BN(R), which is the basis for its ... vector for delivering,recombinant vaccines. Bavarian Nordic has asserted ... action. The claim in this case is that ...
... Hainan, China, Jan. 12 /PRNewswire-Asia-FirstCall/ -- China,Pharma ... CPHI), which,develops, manufactures, and markets specialty pharmaceutical ... Food and Drug Administration ("SFDA"),approved the production ... in the National Medical Insurance Program, thus ...
Cached Biology Technology:Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7Bavarian Nordic's Case Against Oxford BioMedica 2China Pharma Holdings, Inc. Receives SFDA Production Approval for Tiopronin Enteric-Coated Capsules 2China Pharma Holdings, Inc. Receives SFDA Production Approval for Tiopronin Enteric-Coated Capsules 3
(Date:6/17/2015)... , and HILDEN, Germany , June ... QGEN ; Frankfurt Prime Standard: QIA) today launched new Investigator ... in forensic laboratories in the United States ... to simultaneously analyze multiple key genomic markers (short tandem repeats ... Quality Sensor to evaluate the quality of DNA in ...
(Date:6/17/2015)... BEACH GARDENS, Fla. , June 17, 2015 ... management solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... fast casual sandwich chain, to increase security, improve ... Crossmatch fingerprint readers enable instant, non-repudiable identity confirmation ...
(Date:6/16/2015)...  With the increasing number and severity of data ... The recent compromise of Federal employee data from ... within government agencies. HYPR Corp. announced today ... authenticator, has been submitted for testing and approval of ... for tamper proofing. The proliferation of ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... ingredient in the venom of the "deathstalker" scorpion could help ... are reporting. The substance allows therapeutic genes genes that ... current approaches, according to the study in ACS Nano ... that gene therapy the delivery of therapeutic genes into ...
... gallons of oil still in the Gulf of Mexico from ... that consume oil and other hydrocarbons and could break down ... an article in the current issue of Chemical & ... out that the oil-eating bacteria are beneficial in helping to ...
... causes and effects of hypoxia in Green Bay, part of ... year of an anticipated four-year $1,367,300 project through NOAA,s Coastal ... problem for decades, and recent evidence suggests that it may ... kills to become both more frequent and more extensive with ...
Cached Biology News:NOAA awards grant to investigate impacts of land use and climate change on hypoxia in Green Bay 2
Recombinant Rhesus Monkey IFN-Alpha...
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
Biology Products: